English | French | Portuguese | Arabic

Agenda for Africa Pharma Conference 2019

Day 1: 4 June 2019

Opening Ceremony


Welcome Remarks:

This session addresses the broad vision for the conference. It is followed by High Level Statements from principal stakeholders in Africa’s quest to improve universal access to quality assured affordable essential medicines and catalyzing of local production in Africa.

High Level Statements:


10:00-10:15am. Photographs
10.15 – 11.30 hrs. High Level Panel Discussion


This high level session is aimed at discussing the overall continental leadership vision for local production, articulate the issues of political will, national vision and strategies. It will examine the issue of policy coherence and coordination within and between national governments for seamless execution. The session will describe the key steps necessary to champion the growth on an infant local production industry on the African continent.


Talking points include:
• Discuss Political Will, National Vision and Strategies
• What does a coherent policy framework look like – Governmental coordination for seamless execution
• National Champions to drive Infant industry development
• Commitment of funding and creating the right incentive framework


Tea break 11:30-11:45am

11.45 – 13.15 hrs: Strategic continental initiatives

Synopsis of session and talking points
This session will provide an overview of relevant continental initiatives of the African Union and its agencies, which can be explored for critical synergies to advance the agenda of access to medicines, especially as it relates to local production. Information will be provided on the status of implementation, results delivered till date, challenges and processes/interventions necessary to deliver on the overall strategic objectives.




Africa Medicines Regulatory Harmonization (AMRH).

Accelerating Industry Development for Africa (AIDA) :

Accelerating Excellence in Science in Africa (AESA)

Tackling Infections to Benefit Africa (TIBA)


11.45 – 13.15 hrs – Creating the right financial instruments for LPP, Financing initiatives: Origination, Structuring and Execution; including boosting intra-African trade.


Synopsis of session and talking points
The session will start with a brief presentation by Tania Holt, titled: The Opportunity for local pharmaceutical manufacturing in sub-Saharan Africa.
This session will contextualize the realities that confront local production of pharmaceuticals in Africa (LPP) and will provide strategic insights into the opportunities for local production. Given the fact that structuring of financial services and products have not always met the specific requirements of the industry on the continent, the session will highlight some opportunities to access to the financing necessary to support the initiative.



The Opportunity for local pharmaceutical manufacturing in sub-Saharan Africa.





13.15 – 14.15 – Lunch Break

14.15 – 15.30 hrs – The next Frontier for Public Health Medicines Market – rethinking priorities for improved access to quality-assured medicines for Universal Access

Synopsis of session and talking points
With nearly 2 billion people still lacking access to essential medical products and with global pharmaceutical markets becoming less able to respond to the needs of low- and middle-income countries, there is increasing recognition of the importance of developing a high-quality pharmaceutical manufacturing base closer to the patients in need. In 2008, the World Health Assembly adopted the Global Strategy and Plan of Action for Public Health, Innovation and Intellectual Property,” which identified investment in local production of pharmaceuticals as a key area.
Local production of pharmaceuticals confers numerous public health and economic benefits. A strong local pharmaceutical manufacturing base can better respond to demand and limits the risk of supply interruptions. A manufacturing base which is closer to the patient simplifies and shortens the supply chain, facilitating quality assurance.
The discussion will include a brief introductory presentation from two authors of the thought leadership paper, Dr. Skhumbuzo Ngozwana , President & Chief Executive Officer of Kiara Health and international expert on the African Pharmaceutical industry (tbc) and Mr. Kwasi Boateng, Country Director for the USAID funded and USP implemented ‘Promoting the Quality of Medicines Program’, which provides direct technical assistance to pharmaceutical manufacturers globally towards the objective of increasing access to essential public health medicines. The presentation will be followed by a professionally-moderated session to include high level representatives from government, industry and development agencies. Representatives will be asked to share their perspective on key challenges and enablers of local pharmaceutical production.



Tea break 15:30 -15:45am
15.45 – 17.00 hrs - Health and Pharmaceutical Financing; Blended Finance, Scale Readiness for Healthcare companies, Public Private Partnerships and Transaction Structuring


Synopsis of session and talking points
Governments across Africa do not have the resources to solve the most pressing health challenges across the continent. There is a need to find new funding mechanisms to achieve improved healthcare on the continent and attain the and Agenda 2063 and the Sustainable Development Goals (SDGs). This session has become a priority because it will focus on funding models that are scalable and can be leveraged across healthcare and pharmaceutical production across the continent.
The session would explore how structured finance; blended finance and other innovative forms of financing structures can be used to fight Non-Communicable Diseases and Neglected tropical diseases (NTDs) in Africa.





15.45 – 17.00 hrs - Developing LPP – what is the evidence from around the world successful in promoting sustainable local production


Synopsis of session and talking points
There are sections of the developing world and emerging economies have been successful in promoting sustainable local production of pharmaceutical products. This session seeks to highlight these concrete experiences as it relates to the continent and tease out lessons learned that can be adapted to the African realities. Recommendations, which will contribute, to the development and implementation of policy action and programmes will also be proposed.




Leveraging government Procurement as a financial asset for local companies.

Developing LPP, evidence from medicines patent pool around the world.

Voluntary Licenses and Technology Transfer from a local African company to global leader; the case of Aspen.